Related Experiment Video

Updated: Jun 26, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

TGFBI: A novel therapeutic target for cancer

Huimei Huang1, Qinglai Tang1, Shisheng Li1

  • 1Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

International Immunopharmacology
|May 11, 2024
PubMed

Insights

Transforming growth factor beta-induced protein (TGFBI) is linked to cancer progression, affecting cell growth, spread, and immune response. Targeting TGFBI offers a promising therapeutic strategy for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Aberrant expression of Transforming Growth Factor Beta Induced protein (TGFBI) is observed in multiple cancer types.
  • TGFBI is an extracellular matrix protein implicated in tumor cell proliferation, angiogenesis, apoptosis, invasion, and metastasis.
  • TGFBI acts as a marker for epithelial-mesenchymal transition (p-EMT) and correlates with lymph node metastasis, also exhibiting immunosuppressive properties within the tumor microenvironment.

Purpose of the Study:

  • To comprehensively review the multifaceted roles of TGFBI in tumor biology.
  • To examine the impact of TGFBI on cancer cell proliferation, angiogenesis, invasion, metastasis, and apoptosis.
  • To investigate the influence of TGFBI on the tumor immune microenvironment and explore its potential as a therapeutic target.

Main Methods:

  • Literature review of studies on TGFBI in cancer.
  • Analysis of TGFBI's involvement in key oncogenic processes.
  • Exploration of biochemical mechanisms underlying TGFBI's functions in tumors.

Main Results:

  • TGFBI significantly influences tumor cell proliferation, angiogenesis, invasion, and metastasis across various cancers.
  • TGFBI is a key marker for p-EMT and lymph node metastasis, and it suppresses the anti-tumor immune response.
  • Targeted inhibition of TGFBI demonstrates potential as an anti-cancer therapeutic strategy.

Conclusions:

  • TGFBI is a critical factor in cancer progression and immune evasion.
  • Understanding TGFBI's mechanisms provides insights into novel cancer therapies.
  • Targeting TGFBI represents a promising avenue for future cancer treatment development.
Keywords:
CancerImmune microenvironmentMetastasisTGFBI

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K